| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Myricanone targets multiple cellular pathways. It has apoptosis-promoting ability by triggering caspase activation. It suppresses cell proliferation by down-regulating NF-κB and STAT3 signaling cascades. It also shows in vitro testosterone 5α-reductase inhibitory activity. Furthermore, it induces apoptosis in HepG2 cells through the generation of ROS, mitochondrial membrane depolarization, and cytochrome c release.
|
|---|---|
| ln Vitro |
In vitro, Myricanone shows anticancer activity by inducing apoptosis in cancer cells. In HepG2 cells, it induces apoptosis through ROS generation, mitochondrial membrane depolarization, and activation of a caspase cascade. It suppresses cell proliferation via down-regulation of NF-κB and STAT3 signaling. It also exhibits anti-inflammatory activity by inhibiting LPS-induced NO production in mouse RAW264.7 cells.
|
| ln Vivo |
In vivo, Myricanone shows anti-androgenic activity. It inhibits the growth of the flank organ in castrated Syrian hamsters and promotes hair regrowth after shaving in testosterone-treated C57Black/6CrSlc mice. These effects are related to its in vitro testosterone 5α-reductase inhibitory activity. However, detailed in vivo efficacy data for its anticancer activity are limited.
|
| Enzyme Assay |
In vitro enzyme assays for Myricanone typically involve testosterone 5α-reductase inhibition assays. The enzyme is incubated with testosterone and the compound, and the conversion of testosterone to dihydrotestosterone (DHT) is measured. Anti-inflammatory activity is assessed by measuring the inhibition of LPS-induced NO production in RAW264.7 cells using the Griess reagent.
|
| Cell Assay |
In vitro cellular assays for Myricanone are performed using cancer cell lines such as HepG2 or RAW264.7 macrophages. Cells are treated with various concentrations of the compound. Apoptosis is assessed by measuring ROS generation, mitochondrial membrane potential (JC-1 staining), and caspase activation. Cell proliferation is measured using MTT assays. NO production is measured using the Griess reagent.
|
| Animal Protocol |
In vivo animal studies with Myricanone are conducted to assess its anti-androgenic activity. Castrated Syrian hamsters are treated with the compound, and the growth of the flank organ is measured. In another model, testosterone-treated C57Black/6CrSlc mice are treated with the compound, and hair regrowth after shaving is assessed.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of Myricanone are not extensively reported. It has a molecular weight of 356.41. It is a white to off-white solid powder. Its solubility is in DMSO. Specific parameters such as oral bioavailability, half-life, and tissue distribution are not detailed.
|
| Toxicity/Toxicokinetics |
The toxicity profile of Myricanone is not extensively reported. As a research compound, it is for research use only and not for human therapeutic use. No specific toxicity data are detailed in the available literature.
|
| References | |
| Additional Infomation |
Myricanone is a cyclic ketone isolated from the bark of plants in the Morella genus and has been shown to have cytotoxic activity against cancer cells. It is both an antitumor drug and a plant metabolite. Myricanone is a diarylheptane compound, belonging to the aromatic ethers, methoxybenzenes, phenols, and cyclic ketones. It has been reported to exist in Morella cerifera, Morella adenophora, and other organisms with relevant data.
Myricanone is a diarylheptane compound with antioxidant, anticancer, and anti-inflammatory activities. It induces apoptosis via caspase activation and ROS generation and suppresses proliferation by down-regulating NF-κB and STAT3 signaling. It also shows testosterone 5α-reductase inhibitory and anti-androgenic activities. It is available for research purposes only. |
| Molecular Formula |
C21H24O5
|
|---|---|
| Molecular Weight |
356.41226
|
| Exact Mass |
356.162
|
| CAS # |
32492-74-3
|
| PubChem CID |
161748
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
583.7±50.0 °C at 760 mmHg
|
| Melting Point |
194 - 196 °C
|
| Flash Point |
206.7±23.6 °C
|
| Vapour Pressure |
0.0±1.7 mmHg at 25°C
|
| Index of Refraction |
1.581
|
| LogP |
3.49
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
26
|
| Complexity |
467
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
ZTSNTUQTNQSIDC-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C21H24O5/c1-25-20-17-12-14(19(24)21(20)26-2)5-3-4-6-15(22)9-7-13-8-10-18(23)16(17)11-13/h8,10-12,23-24H,3-7,9H2,1-2H3
|
| Chemical Name |
3,15-dihydroxy-16,17-dimethoxytricyclo[12.3.1.12,6]nonadeca-1(17),2,4,6(19),14(18),15-hexaen-9-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8058 mL | 14.0288 mL | 28.0576 mL | |
| 5 mM | 0.5612 mL | 2.8058 mL | 5.6115 mL | |
| 10 mM | 0.2806 mL | 1.4029 mL | 2.8058 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
